Tymoteusz Poprawski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tymoteusz Poprawski has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Marcin Jędryka
Department of Oncology, Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland
3 shared publications - Jan Hojný
Department of Pathology, 1st Faculty of Medicine Charles University, General University Hospital Prague Czech Republic
2 shared publications - Krzysztof Grobelak
Department of Oncologic Gynecology, Lower Silesian Oncology, Hematology and Pulmonology Center, 53-413 Wroclaw, Poland
2 shared publications Michaela Kendall Bártů
Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague
2 shared publications- Pavel Dundr
Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 2, Czech Republic
2 shared publications - Radoslav Matěj
Department of Pathology, 3rd Faculty of Medicine Charles University, University Hospital Kralovske Vinohrady Prague Czech Republic
2 shared publications
Latest Publications
- 11 September 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 50 (12) , 1488-1497
Uterine Sarcomas With KDM2B Fusion: Clinicopathological Analysis of Three Cases Supporting a Novel BCOR-Altered Entity
High-grade endometrial stromal sarcomas (HGESS) with BCOR-alteration include sarcomas with YWHAE::NUTM2A/B fusion, ZC3H7B::BCOR fusion, BCOR -ITD, BCOR alternative fusion, and BCORL1 fusion. Recently, 4 cases of uterine sarcomas with KDM2B fusion have been described, which were suggested to belong to the category of BCOR-altered tumors. These tumors are characterized by recurrent fusions of the KDM2B gene with fusion partners including EPC1 , EP400 , and CITED1 . Morphologically, some of them may have a nonspecific spindle-cell or round-cell appearance. In other tumors, however, peculiar morphologic features combining atypical round cells with at least focal sex cord-like features and myxoid stroma were found. In our study, we described 3 additional cases of uterine sarcomas with KDM2B fusion, with fusion partners including EPC1 , EPC2 , and CREBBP . Morphologically, these tumors showed either pure spindle-cell morphology, a combination of spindle and round cells, or a heterogeneous pattern with spindle cells, round cells, and prominent hyalinization, with only focal, vague sex cord-like features. Despite possible morphologic overlap with low-grade endometrial stromal sarcomas in some cases, these tumors seem to represent a variant of HGESS belonging to the category of BCOR-altered sarcomas and have a propensity for aggressive behavior, as 2 of our patients died of disease, and the third had pelvic recurrence before being lost to follow-up.
- 11 September 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 50 (12) , 1488-1497
Uterine Sarcomas With KDM2B Fusion: Clinicopathological Analysis of Three Cases Supporting a Novel BCOR-Altered Entity
High-grade endometrial stromal sarcomas (HGESS) with BCOR-alteration include sarcomas with YWHAE::NUTM2A/B fusion, ZC3H7B::BCOR fusion, BCOR -ITD, BCOR alternative fusion, and BCORL1 fusion. Recently, 4 cases of uterine sarcomas with KDM2B fusion have been described, which were suggested to belong to the category of BCOR-altered tumors. These tumors are characterized by recurrent fusions of the KDM2B gene with fusion partners including EPC1 , EP400 , and CITED1 . Morphologically, some of them may have a nonspecific spindle-cell or round-cell appearance. In other tumors, however, peculiar morphologic features combining atypical round cells with at least focal sex cord-like features and myxoid stroma were found. In our study, we described 3 additional cases of uterine sarcomas with KDM2B fusion, with fusion partners including EPC1 , EPC2 , and CREBBP . Morphologically, these tumors showed either pure spindle-cell morphology, a combination of spindle and round cells, or a heterogeneous pattern with spindle cells, round cells, and prominent hyalinization, with only focal, vague sex cord-like features. Despite possible morphologic overlap with low-grade endometrial stromal sarcomas in some cases, these tumors seem to represent a variant of HGESS belonging to the category of BCOR-altered sarcomas and have a propensity for aggressive behavior, as 2 of our patients died of disease, and the third had pelvic recurrence before being lost to follow-up.
- Open Access
Superparamagnetic Iron Oxide Used Alone Is Non-Inferior to the Combination of Radioactive Tracer and Superparamagnetic Iron Oxide in Detecting Sentinel Lymph Nodes in Early-Stage Vulvar Cancer
Background: Radioactive colloids are considered the standard of care for sentinel lymph node (SLN) detection. An alternative detection method using superparamagnetic iron oxide (SPIO) nanoparticles is well documented in breast cancer but poorly studied for gynecological tumors, including vulvar cancer (VC). Objective: Our aim was to evaluate the feasibility, accuracy, and safety of SPIO nanoparticles for SLN mapping in patients with VC as a stand-alone technique compared with the combination of two methods: the standard of care using a radioactive isotope (technetium-99; Tc-99) and SPIO as a new tracer. Methods: We conducted a prospective and observational study of SLN mapping in patients with stage IB VC and tumor size ≤ 4 cm. We calculated detection and malignancy rates per patient and per groin in both study groups. During the 36-month follow-up, the groin recurrence rate was estimated for positive and negative SLNs. Kaplan–Meyer curves were used to analyze the probability of survival, depending on disease-free survival. Results: A total of 110 groins assessed by SLN in 60 patients included in this study were analyzed (70 groins from 40 patients in the group with a single tracer and 40 groins from 20 patients in the group of combined tracers). At least one sentinel lymph node was detected in every patient while the bilateral detection rate was 92.3% for the SPIO group and 88.2% for the Tc-99 and SPIO group. The groin detection rate was 94.3% and 90%, respectively. SLN mapping failure was similar in both groups (2.8% and 2.5%, respectively). During a 3-year follow-up, the isolated groin recurrence rate was 2.1% for negative groins and for disease-free survival it was 28.9 months in the combined tracer group versus 32.8 months in the SPIO group. The Kaplan–Meyer curves showed the increased probability of survival for the SPIO group (87.5%); however, it was insignificant. Conclusions: SLN mapping using the SPIO technique in patients with VC is non-inferior to the combined SPIO and Tc-99 method.
Open AccessSuperparamagnetic Iron Oxide Used Alone Is Non-Inferior to the Combination of Radioactive Tracer and Superparamagnetic Iron Oxide in Detecting Sentinel Lymph Nodes in Early-Stage Vulvar Cancer
Background: Radioactive colloids are considered the standard of care for sentinel lymph node (SLN) detection. An alternative detection method using superparamagnetic iron oxide (SPIO) nanoparticles is well documented in breast cancer but poorly studied for gynecological tumors, including vulvar cancer (VC). Objective: Our aim was to evaluate the feasibility, accuracy, and safety of SPIO nanoparticles for SLN mapping in patients with VC as a stand-alone technique compared with the combination of two methods: the standard of care using a radioactive isotope (technetium-99; Tc-99) and SPIO as a new tracer. Methods: We conducted a prospective and observational study of SLN mapping in patients with stage IB VC and tumor size ≤ 4 cm. We calculated detection and malignancy rates per patient and per groin in both study groups. During the 36-month follow-up, the groin recurrence rate was estimated for positive and negative SLNs. Kaplan–Meyer curves were used to analyze the probability of survival, depending on disease-free survival. Results: A total of 110 groins assessed by SLN in 60 patients included in this study were analyzed (70 groins from 40 patients in the group with a single tracer and 40 groins from 20 patients in the group of combined tracers). At least one sentinel lymph node was detected in every patient while the bilateral detection rate was 92.3% for the SPIO group and 88.2% for the Tc-99 and SPIO group. The groin detection rate was 94.3% and 90%, respectively. SLN mapping failure was similar in both groups (2.8% and 2.5%, respectively). During a 3-year follow-up, the isolated groin recurrence rate was 2.1% for negative groins and for disease-free survival it was 28.9 months in the combined tracer group versus 32.8 months in the SPIO group. The Kaplan–Meyer curves showed the increased probability of survival for the SPIO group (87.5%); however, it was insignificant. Conclusions: SLN mapping using the SPIO technique in patients with VC is non-inferior to the combined SPIO and Tc-99 method.
- Open Access
- 26 May 2025
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 16 (6) , 196
Diagnostic Value of Superparamagnetic Iron Oxide Nanoparticles as a Tracer for Sentinel Lymph Node Mapping in Early-Stage Cervical Cancer: The Preliminary Clinical Experience
Sentinel lymph node (SLN) mapping has been investigated as part of surgical staging in women with early-stage cervical cancer (CC); however, pelvic lymphadenectomy (PLND) remains the standard of care. This study aimed to assess feasibility and safety of SLN detection using superparamagnetic iron oxide (SPIO) nanoparticles as a tracer in CC. Thirty CC patients presumed to be stage I were included in this study with SPIO administered intracervically as a tracer for SLN mapping using a magnetometer and followed by PLND. The endpoints of the study included the proportion of successful SLN detection, the average number of SLNs per patient, and the proportion of pathologically positive results per patient and per node. The diagnostic accuracy of SPIO nanoparticles for detection of metastatic SLNs was evaluated by Receiver Operating Characteristic (ROC) curve analysis, with the area under the ROC curve (AUC) used to demonstrate the studied method’s sensitivity. Safety endpoints were a summary of all reported adverse events. SLNs were detected in all cases, bilaterally in 27 patients (90%). The median number of SLNs per patient was 3.5. Four cases had metastatic SLNs. The general malignancy rate per patient was 13.3%, and per node, it was 0.8%. The malignancy detection rate of SLNs was 100% per patient and 80% per node. The AUC of 1.0 (p < 0.001) confirmed the diagnostic value of the SPIO technique for the detection of metastatic SLNs, with a sensitivity of 100%. No adverse events related to the SPIO administration were reported. SPIO nanoparticles, as a tracer for SLN mapping in early-stage CC patients, demonstrated satisfactory accuracy parameters and safety; however, these data need to be evaluated by further research.
- 26 May 2025
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 16 (6) , 196
Open AccessDiagnostic Value of Superparamagnetic Iron Oxide Nanoparticles as a Tracer for Sentinel Lymph Node Mapping in Early-Stage Cervical Cancer: The Preliminary Clinical Experience
Sentinel lymph node (SLN) mapping has been investigated as part of surgical staging in women with early-stage cervical cancer (CC); however, pelvic lymphadenectomy (PLND) remains the standard of care. This study aimed to assess feasibility and safety of SLN detection using superparamagnetic iron oxide (SPIO) nanoparticles as a tracer in CC. Thirty CC patients presumed to be stage I were included in this study with SPIO administered intracervically as a tracer for SLN mapping using a magnetometer and followed by PLND. The endpoints of the study included the proportion of successful SLN detection, the average number of SLNs per patient, and the proportion of pathologically positive results per patient and per node. The diagnostic accuracy of SPIO nanoparticles for detection of metastatic SLNs was evaluated by Receiver Operating Characteristic (ROC) curve analysis, with the area under the ROC curve (AUC) used to demonstrate the studied method’s sensitivity. Safety endpoints were a summary of all reported adverse events. SLNs were detected in all cases, bilaterally in 27 patients (90%). The median number of SLNs per patient was 3.5. Four cases had metastatic SLNs. The general malignancy rate per patient was 13.3%, and per node, it was 0.8%. The malignancy detection rate of SLNs was 100% per patient and 80% per node. The AUC of 1.0 (p < 0.001) confirmed the diagnostic value of the SPIO technique for the detection of metastatic SLNs, with a sensitivity of 100%. No adverse events related to the SPIO administration were reported. SPIO nanoparticles, as a tracer for SLN mapping in early-stage CC patients, demonstrated satisfactory accuracy parameters and safety; however, these data need to be evaluated by further research.
- 24 May 2025
- Published by Elsevier in Laboratory Investigation
- Vol. 105 (9) , 104198
Decoding the Molecular Landscape of 262 Uterine Sarcomas: RNA-Seq Clustering of Endometrial Stromal Sarcomas, Uterine Tumors Resembling Ovarian Sex Cord Tumors, and Undifferentiated Uterine Sarcomas With Prognostic Insights
- 24 May 2025
- Published by Elsevier in Laboratory Investigation
- Vol. 105 (9) , 104198
Decoding the Molecular Landscape of 262 Uterine Sarcomas: RNA-Seq Clustering of Endometrial Stromal Sarcomas, Uterine Tumors Resembling Ovarian Sex Cord Tumors, and Undifferentiated Uterine Sarcomas With Prognostic Insights